155 related articles for article (PubMed ID: 31007848)
1. AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer.
Goyette MA; Cusseddu R; Elkholi I; Abu-Thuraia A; El-Hachem N; Haibe-Kains B; Gratton JP; Côté JF
Oncotarget; 2019 Mar; 10(21):2055-2067. PubMed ID: 31007848
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop.
Shen Y; Zhu Q; Xiao M; Yin L; Feng W; Feng J; He J; Li P; Chen X; Ding W; Zhong J; Zeng Z; Xie Z; Liu J; Zu X
Cell Death Dis; 2022 Aug; 13(8):749. PubMed ID: 36042208
[TBL] [Abstract][Full Text] [Related]
4. AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.
Bottai G; Raschioni C; Székely B; Di Tommaso L; Szász AM; Losurdo A; Győrffy B; Ács B; Torrisi R; Karachaliou N; Tőkés T; Caruso M; Kulka J; Roncalli M; Santoro A; Mantovani A; Rosell R; Reis-Filho JS; Santarpia L
NPJ Breast Cancer; 2016; 2():16033. PubMed ID: 28721387
[TBL] [Abstract][Full Text] [Related]
5. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
6. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
7. E1A-mediated inhibition of HSPA5 suppresses cell migration and invasion in triple-negative breast cancer.
Chen HA; Chang YW; Tseng CF; Chiu CF; Hong CC; Wang W; Wang MY; Hsiao M; Ma JT; Chen CH; Jiang SS; Wu CH; Hung MC; Huang MT; Su JL
Ann Surg Oncol; 2015 Mar; 22(3):889-98. PubMed ID: 25212833
[TBL] [Abstract][Full Text] [Related]
8. GPER mediates enhanced cell viability and motility via non-genomic signaling induced by 17β-estradiol in triple-negative breast cancer cells.
Yu T; Liu M; Luo H; Wu C; Tang X; Tang S; Hu P; Yan Y; Wang Z; Tu G
J Steroid Biochem Mol Biol; 2014 Sep; 143():392-403. PubMed ID: 24874276
[TBL] [Abstract][Full Text] [Related]
9. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
11. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer.
Huang SP; Liu PY; Kuo CJ; Chen CL; Lee WJ; Tsai YH; Lin YF
J Hematol Oncol; 2017 Jun; 10(1):114. PubMed ID: 28576130
[TBL] [Abstract][Full Text] [Related]
12. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
13. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
15. Triple‑negative breast cancer cells that survive ionizing radiation exhibit an Axl‑dependent aggressive radioresistant phenotype.
Ji J; Ding Y; Kong Y; Fang M; Yu X; Lai X; Gu Q
Exp Ther Med; 2023 Sep; 26(3):448. PubMed ID: 37614420
[TBL] [Abstract][Full Text] [Related]
16. Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases.
Xu F; Xia Y; Feng Z; Lin W; Xue Q; Jiang J; Yu X; Peng C; Luo M; Yang Y; Wei Y; Yu L
Am J Cancer Res; 2019; 9(3):459-478. PubMed ID: 30949404
[TBL] [Abstract][Full Text] [Related]
17. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
18. Drug Repurposing for Triple-Negative Breast Cancer.
Ávalos-Moreno M; López-Tejada A; Blaya-Cánovas JL; Cara-Lupiañez FE; González-González A; Lorente JA; Sánchez-Rovira P; Granados-Principal S
J Pers Med; 2020 Oct; 10(4):. PubMed ID: 33138097
[TBL] [Abstract][Full Text] [Related]
19. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
[TBL] [Abstract][Full Text] [Related]
20. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
